MX2021005273A - Inhibidores de quinasa rock. - Google Patents

Inhibidores de quinasa rock.

Info

Publication number
MX2021005273A
MX2021005273A MX2021005273A MX2021005273A MX2021005273A MX 2021005273 A MX2021005273 A MX 2021005273A MX 2021005273 A MX2021005273 A MX 2021005273A MX 2021005273 A MX2021005273 A MX 2021005273A MX 2021005273 A MX2021005273 A MX 2021005273A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
compounds
methods
present
rock kinase
Prior art date
Application number
MX2021005273A
Other languages
English (en)
Inventor
Matthew Randolph Lee
Anthony Joseph Varano
Original Assignee
Cervello Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cervello Therapeutics LLC filed Critical Cervello Therapeutics LLC
Publication of MX2021005273A publication Critical patent/MX2021005273A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos que inhiben la actividad de ROCK; en particular, la presente invención se refiere a compuestos, composiciones farmacéuticas y métodos de uso, tales como métodos para inhibir la actividad ROCK y métodos para tratar, por ejemplo, el síndrome de malformación cavernosa cerebral (CCM) y enfermedades cardiovasculares usando los compuestos y composiciones farmacéuticas de la presente invención.
MX2021005273A 2018-11-06 2019-11-06 Inhibidores de quinasa rock. MX2021005273A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862756202P 2018-11-06 2018-11-06
PCT/US2019/059992 WO2020097158A1 (en) 2018-11-06 2019-11-06 Rock kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2021005273A true MX2021005273A (es) 2021-09-08

Family

ID=70459339

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005273A MX2021005273A (es) 2018-11-06 2019-11-06 Inhibidores de quinasa rock.

Country Status (13)

Country Link
US (1) US10745381B2 (es)
EP (1) EP3877364A4 (es)
JP (1) JP2022506572A (es)
KR (1) KR20210093269A (es)
CN (1) CN113227054A (es)
AU (1) AU2019377087A1 (es)
BR (1) BR112021008883A2 (es)
CA (1) CA3118738A1 (es)
EA (1) EA202191164A1 (es)
IL (1) IL282941A (es)
MX (1) MX2021005273A (es)
SG (1) SG11202104446UA (es)
WO (2) WO2020097158A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113582926B (zh) * 2021-09-09 2022-03-01 安徽有吉医药科技有限公司 4-氟异喹啉-5-磺酰氯或其药学上可接受的盐的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049468B2 (en) * 2001-11-19 2006-05-23 Iconix Pharmaceuticals, Inc. Modulators of Rho C activity
US20040266755A1 (en) 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
ATE423779T1 (de) * 2005-04-25 2009-03-15 Western Therapeutics Inst Inc Hochselektiver rho-kinase-inhibitor
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
CA2926478C (en) 2012-10-05 2022-05-24 Kadmon Corporation, Llc Rho kinase inhibitors
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP6581111B2 (ja) * 2014-04-28 2019-09-25 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
TWI699207B (zh) * 2015-08-31 2020-07-21 日商興和股份有限公司 拉巴斯吉之用於製造眼壓下降增強劑之用途
KR102473481B1 (ko) 2016-07-07 2022-12-01 브리스톨-마이어스 스큅 컴퍼니 강력하고 선택적인 rock 억제제로서의 락탐, 시클릭 우레아 및 카르바메이트, 및 트리아졸론 유도체
CN109661396B (zh) 2016-07-07 2022-07-01 百时美施贵宝公司 作为rock抑制剂的螺稠合环状脲
JP7113810B2 (ja) 2016-07-07 2022-08-05 ブリストル－マイヤーズ スクイブ カンパニー Ｒｏｃｋ阻害剤としてのスピロラクタム
JP7117306B2 (ja) * 2016-12-21 2022-08-12 バイオアクソン バイオサイエンシーズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物
JP7234201B2 (ja) 2017-07-12 2023-03-07 ブリストル－マイヤーズ スクイブ カンパニー 心不全の治療のためのｒｏｃｋの５員アミノヘテロ環および５，６－または６，６員二環式アミノヘテロ環の阻害剤
US11447487B2 (en) 2017-07-12 2022-09-20 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as rock inhibitors
TW201908293A (zh) 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
KR102680164B1 (ko) 2017-07-12 2024-07-01 브리스톨-마이어스 스큅 컴퍼니 Rock 억제제로서의 페닐아세트아미드

Also Published As

Publication number Publication date
AU2019377087A1 (en) 2021-06-03
JP2022506572A (ja) 2022-01-17
EP3877364A1 (en) 2021-09-15
CN113227054A (zh) 2021-08-06
US20200140412A1 (en) 2020-05-07
EA202191164A1 (ru) 2022-01-24
EP3877364A4 (en) 2022-08-03
WO2020097158A1 (en) 2020-05-14
IL282941A (en) 2021-06-30
KR20210093269A (ko) 2021-07-27
BR112021008883A2 (pt) 2021-08-10
WO2021091593A1 (en) 2021-05-14
US10745381B2 (en) 2020-08-18
SG11202104446UA (en) 2021-05-28
CA3118738A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
MX2022002465A (es) Inhibidores de kras g12d.
PH12020550622A1 (en) Kras g12c inhibitors
AU2018236800B2 (en) DNA-PK inhibitors
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2021015106A (es) Inhibidores de ferroportina novedosos.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2022002938A (es) Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta).
PH12017501925A1 (en) Pyrazole compounds and method for making and using the compounds
SA517390509B1 (ar) مركب مشتق ثلاثي الحلقات، وطريقة لتحضيره ، وتركيبة صيدلانية تشتمل عليه
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
EA033163B1 (ru) Ингибиторы глутаминазы
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
PH12018500423A1 (en) Inhibitors of ezh2
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
GEP20227442B (en) Boron containing pde4 inhibitors
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
MX2021005273A (es) Inhibidores de quinasa rock.
MX2023001721A (es) Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer.
MX2020010577A (es) Derivados de morfolina como inhibidores de vps34.
EA201792676A1 (ru) Ингибиторы jak1